1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">http://doi.org/10.1378/chest.125.5.1888</a>
Pages
1888–1901
Issue
5
Volume
125
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Chest
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-05
Subject
The topic of the resource
Humans; United States; Practice Guidelines as Topic; Canada; Europe; Community-Acquired Infections/drug therapy; Fluoroquinolones/therapeutic use; Lactams/therapeutic use; Macrolides/therapeutic use; Drug Resistance; Pneumonia; Bacterial; Bacterial/*drug therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Garau Javier; Blasi Francesco; Chidiac Christian; Klugman Keith; Lode Hartmut; Lonks John R; Mandell Lionel; Ramirez Julio; Yu Victor
Description
An account of the resource
Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient setting. The North American approach is to use initial antimicrobial therapy, which provides coverage for Streptococcus pneumoniae plus atypical pathogens. Europeans tend to focus on providing pneumococcal coverage with less emphasis on covering for an atypical pathogen. Ambulatory patients without comorbidity are more likely to receive macrolide therapy in North America, whereas in Europe these patients would probably receive a beta-lactam agent. Major issues that are fundamental to this difference include the importance of providing therapy for atypical pathogens and the clinical significance of macrolide-resistant S pneumoniae. Prospective data are required to evaluate which of these two approaches offers clinical superiority.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">10.1378/chest.125.5.1888</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Bacterial
Bacterial/*drug therapy
Blasi Francesco
Canada
Chest
Chidiac Christian
Community-Acquired Infections/drug therapy
Department of Internal Medicine
Drug Resistance
Europe
File Thomas M Jr
Fluoroquinolones/therapeutic use
Garau Javier
Humans
Klugman Keith
Lactams/therapeutic use
Lode Hartmut
Lonks John R
Macrolides/therapeutic use
Mandell Lionel
NEOMED College of Medicine
Pneumonia
Practice Guidelines as Topic
Ramirez Julio
United States
Yu Victor